Saxenda

Saxenda (liraglutide 3ml injection pen) is an prescription medication for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related conditions. Clinical trials demonstrate 56% of patients achieved ≥5% weight loss at 56 weeks when combined with lifestyle changes, with an average 8% body weight reduction. As a GLP-1 receptor agonist, it suppresses appetite by delaying gastric emptying by 31% and enhances satiety, while improving metabolic health markers like HbA1c (-0.6%) and systolic blood pressure (-2.8mmHg).